Galaxy CCRO was established by a team of clinicians and scientists united by a shared frustration with the inadequate management of stroke. Our mission is to unlock the potential of underexploited biomarkers and near-patient diagnostic technologies to significantly improve the speed and accuracy of ischemic stroke diagnosis and treatment.
While Corpus Christi, Texas, serves as our operational home, our work extends across an expansive global network of clinicians, researchers, and scientists. Strong collaborative partnerships throughout the European Union complement and strengthen our North American research programs, ensuring balanced, world-class development across regions.
Join Us in Making a Difference
Invest in the advancement of life-saving diagnostic technology. Supporting Galaxy CCRO means accelerating innovation, improving patient outcomes, and saving lives on a global scale.
Clinical Advancement
More than 15 million strokes occur each year worldwide, creating urgent and sustained demand for faster, more reliable diagnostic solutions.
Strategic Partnerships
Galaxy CCRO has secured a technology licensing agreement with Proteome Sciences, leveraging elite expertise in proteomics and biomarker science.
Experienced Leadership
Our leadership team combines decades of experience across emergency medicine, proteomics, clinical research, and business development, ensuring disciplined execution and scalable growth.